hMG 75iu Injection (Menotrophin)

Product Overview

hMG 75iu Injection (Menotrophin) is a biologically derived gonadotropin preparation used to support reproductive function in both women and men. The product is manufactured by Sanzyme Biologics (P) Ltd and is supplied as a single injection in a sealed vial. It is indicated for the treatment of female infertility associated with ovulatory disorders and for male hypogonadism and infertility linked to insufficient pituitary gonadotropin activity. The medication is available in pack sizes of ten, twenty or five vials, each containing one injection of 75 international units of human menopausal gonadotropin. Storage requires refrigeration between two and eight degrees Celsius and protection from light. The preparation is intended for use under the supervision of a qualified healthcare professional. FDA provides regulatory details.

What is hMG 75iu Injection (Menotrophin)

hMG 75iu Injection (Menotrophin) belongs to a class of hormonal agents known as menotropins, which are extracted from the urine of post‑menopausal women. The active component mimics the natural luteinizing hormone and follicle‑stimulating hormone that regulate ovarian follicular development and testicular testosterone production. Although the exact molecular composition is not disclosed as an active ingredient on the label, the preparation is recognized by regulatory authorities as a standardized gonadotropin extract. It is administered by subcutaneous or intramuscular injection after reconstitution with the provided diluent. The product is classified as a prescription medication and should only be obtained through licensed pharmacy channels. NIH offers scientific background.

Uses and Benefits

The primary therapeutic use of hMG 75iu Injection (Menotrophin) is to stimulate the development of multiple ovarian follicles in women undergoing controlled ovarian hyperstimulation for assisted reproductive techniques such as in‑vitro fertilisation. In men, the same preparation can enhance endogenous testosterone synthesis, thereby improving parameters of male hypogonadism such as low libido and reduced muscle mass. Clinical studies cited by the National Institutes of Health indicate that treatment cycles employing this agent may increase the number of mature oocytes retrieved and improve sperm concentration in selected patient groups. Benefits are generally observed after several treatment cycles and are most pronounced when combined with lifestyle optimisation and nutritional support. Patients often report improved menstrual regularity and enhanced energy levels, reflecting the hormonal balance achieved through supplementation.

How It Works

hMG 75iu Injection (Menotrophin) functions by providing exogenous gonadotropin activity that stimulates the ovaries to mature multiple follicles simultaneously or prompts the testes to produce additional testosterone. The hormone complex binds to luteinizing hormone and follicle‑stimulating hormone receptors on granulosa and theca cells in the ovary, as well as on Leydig cells in the testes, leading to increased production of estrogen and androgen respectively. This dual action creates a favourable endocrine environment for gamete maturation and implantation. The mechanism is similar to that of naturally occurring gonadotropins, but the exogenous source allows for controlled dosing and predictable pharmacodynamic response. The product does not contain any synthetic analogues; rather it relies on the physiological potency of purified urinary gonadotropins.

Dosage Guidelines

Dosage of hMG 75iu Injection (Menotrophin) is individualized based on patient age, baseline hormone levels and the specific clinical protocol employed. In reproductive endocrinology, a typical initiating dose ranges from one to two vials administered subcutaneously over a period of several days, with adjustments guided by serial ultrasound monitoring and serum estradiol measurements. For male patients, a lower frequency of administration is often recommended, with injections given at intervals of one to two weeks to maintain adequate testosterone levels. It is essential that dosing decisions are made by a qualified clinician who can interpret laboratory results and adjust the regimen accordingly. Patients should never self‑administer the medication without prior medical evaluation and instruction.

Side Effects

Like all hormonal therapies, hMG 75iu Injection (Menotrophin) can be associated with adverse effects, although many are mild and transient. Common side effects include mild abdominal discomfort, headache, and transient injection site irritation. Less frequently, patients may experience ovarian hyperstimulation syndrome, characterised by abdominal bloating, nausea and rapid weight gain, which requires immediate medical attention. In men, potential side effects comprise acne, increased body hair and fluid retention. Rarely, allergic reactions such as rash or respiratory distress may occur. NIH provides detailed safety data. Anyone experiencing severe or persistent symptoms should contact their healthcare provider promptly. The safety profile of the product is considered favourable when used according to prescribed protocols and under professional supervision.

Warnings and Precautions

Prior to initiating treatment with hMG 75iu Injection (Menotrophin), clinicians should assess for contraindications such as known ovarian cysts, unexplained vaginal bleeding and certain types of hormone‑sensitive cancers. Patients with a history of thromboembolic disorders should be evaluated carefully, as hormonal stimulation may increase clotting risk. Pregnant or breastfeeding individuals must avoid use, as the medication may affect fetal development. It is advisable to obtain baseline liver function tests and lipid panels before beginning therapy. Concomitant use of other hormonal medications should be reviewed to prevent excessive dosing. Finally, all patients should be counselled on the importance of regular follow‑up visits to monitor response and to adjust treatment as needed. Information on safe handling and disposal of unused vials can be found on the MedlinePlus website.

Frequently Asked Questions

Question 1: What condition does hMG 75iu Injection (Menotrophin) treat?

Answer: It is indicated for female infertility due to ovulatory dysfunction and for male hypogonadism and infertility associated with low gonadotropin levels.

Question 2: How is the medication administered?

Answer: The vial is reconstituted with the supplied diluent and injected either subcutaneously or intramuscularly as directed by a healthcare professional.

Question 3: Can the product be used for weight loss?

Answer: No, this medication is not intended for weight management and should only be used for its approved reproductive indications.

Question 4: Is refrigeration required?

Answer: Yes, the vials must be stored in a refrigerator at a temperature between two and eight degrees Celsius and protected from light until use.

Question 5: Where can I find more scientific information?

Answer: Details regarding clinical studies and regulatory status are available from the NIH PubMed database and the FDA’s drug information portal.

Related Products

• Letrozole 2.5 mg (Generic)
• Estradiol 2 mg (Generic)
• Progesterone 50 mg Injection (Generic)
• Menotropin HMG 150iu Injection (Generic)
• Menotropin HMG 75iu Injection (Generic)
• IVFhMG 75iu (Menotrophin [HMG])
• IVFhMG 150iu (Menotrophin [HMG])
• hMG 1200iu Injection (Menotrophin)
• hCG 10000iu Injection (Human Chorionic Gonadotropin)
• hCG 5000iu Injection (Human Chorionic Gonadotropin)
• hMG 150iu Injection (Menotrophin)
• ZyHMG 75iu Injection (Menotrophin [HMG])